

Reducing mutant Huntingtin protein expression in living cells by a newly identified RNA CAG binder

Frank Matthes^{1, ‡}, Serena Massari^{2, ‡}, Anna Bochicchio^{3, ‡}, Kenji Schorpp^{4, ‡}, Judith Schilling^{1, ‡}, Stephanie Weber¹, Nina Offermann¹, Jenny Desantis², Erich Wanker⁵, Paolo Carloni^{3,6}, Kamyar Hadian⁴, Oriana Tabarrini^{2,*}, Giulia Rossetti^{3,7,8,*}, Sybille Krauss^{1,*}

1 German Center for Neurodegenerative Diseases (DZNE), Sigmund-Freud-Str.27, 53127 Bonn, Germany

2 Department of Pharmaceutical Science, University of Perugia, Via del Liceo 1, 06123 Perugia, Italy

3 Computational Biomedicine, Institute for Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich, 52425 Jülich, Germany

4 Assay Development and Screening Platform, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München für Gesundheit und Umwelt, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany

5 Neuroproteomics, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Str. 10, 13092 Berlin, Germany


6 JARA-HPC, Jülich Supercomputing Centre, Forschungszentrum Jülich GmbH, 52425 Jülich, Germany

7 Jülich Supercomputing Centre (JSC), Forschungszentrum Jülich, 52425 Jülich, Germany


8 Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany

SUPPORTING INFORMATION

SUPPLEMENTARY FIGURES




























Supplementary Figure S1: Full-length blot of Figure 2a.



Supplementary Figure S2: Furamidine does not affect the protein level of endogenous non-mutant polyglutamine proteins. HEK293T-cells were treated with or without different doses of furamidine for 24 hours. (a) HTT protein level was analyzed on a western blot using anti-HTT antibodies for detection. Actin was detected as loading control. (b) Ataxin-2 and Ataxin-3 protein level was analyzed on a western blot using anti-Ataxin-2 or anti-Ataxin-3 antibodies for detection. Tubulin was detected as loading control. A representative western blot of an n=3 experiments together with quantification of relative protein levels is shown. Mean values +/- SEM are shown.

Supplementary Table

Table S1. Chemical structure of the 25 molecules selected in this study.	
 <p>bis(4-((dimethylamino)methyl)phenyl)methanone C₁₉H₂₄N₂O</p>	 <p>Amb8480308 3,3'-carbonylbis(azanediyl)dibenzimidamide C₁₅H₁₆N₆O</p>
 <p>bis(2-(4-aminophenyl)-1H-benzot[4,5-d]imidazol-6-yl)methanone C₂₇H₂₀N₆O</p>	 <p>1,3-bis(4-(pyrrolidin-1-ylmethyl)phenyl)urea C₂₃H₃₀N₄O</p>
 <p>1,1'-(4,4'-carbonylbis(4,1-phenylene))bis(3-methyl-1H-imidazol-3-ium) iodide C₂₁H₂₀I₂N₄O</p>	 <p>2,2'-(1,1'-(4,4'-carbonylbis(azanediyl))bis(4,1-phenylene))bis(ethan-1-yl-1-ylidene))bis(hydrazinecarboximidamide) C₁₉H₂₄N₁₀O</p>
 <p>4,4'-oxydibenzimidamide C₁₄H₁₄N₄O</p>	 <p>1,3-bis(4-((4-methylpiperazin-1-yl)methyl)phenyl)urea C₂₅H₃₆N₆O</p>
 <p>1,1'-(4,4'-oxybis(4,1-phenylene))dipiperazine C₂₀H₂₆N₄O</p>	 <p>Amb8201157 1,3-bis(2-methyl-4-(4-methylpiperazin-1-yl)phenyl)urea C₂₅H₃₆N₆O</p>
 <p><i>tert</i>-butyl 4,4'-(9-oxo-9H-xanthene-3,6-diyl)dipiperazine-1-carboxylate C₃₁H₄₀N₄O₆</p>	 <p>1-(4-(aminomethyl)phenyl)-3-(4-(dimethylamino)phenyl)urea C₁₆H₂₀N₄O</p>
 <p>furamidine dihydrochloride 4,4'-(furan-2,5-diyl)dibenzimidamide dihydrochloride C₁₈H₁₈Cl₂N₄O</p>	 <p>1,3-bis(4-(diethylamino)phenyl)urea C₂₁H₃₀N₄O</p>

 <p>nafamostat dimesylate 6-carbamimidoylnaphthalen-2-yl 4-(diaminomethyleneamino)benzoate dimethanesulfonate $C_{21}H_{25}N_5O_8S_2$</p>	 <p>1,3-bis(4-(dimethylamino)phenyl)urea $C_{17}H_{22}N_4O$</p>
 <p>6-carbamimidoylnaphthalen-2-yl 4-(aminomethyl)benzoate $C_{19}H_{17}N_3O_2$</p>	 <p>1-(4-(dimethylamino)phenyl)-3-(2-methylbenzo[d]thiazol-6-yl)urea $C_{17}H_{18}N_4OS$</p>
 <p>6-carbamimidoylnaphthalen-2-yl 4-(4,5-dihydro-1H-imidazol-2-ylamino)benzoate $C_{21}H_{19}N_5O_2$</p>	 <p>Amb10790058 1,3-bis(4-((2-methyl-1H-imidazol-1-yl)methyl)phenyl)urea $C_{23}H_{24}N_6O$</p>
 <p>4-(aminomethyl)-N-(4-((dimethylamino)methyl)phenyl)benzamide $C_{17}H_{21}N_3O$</p>	 <p>1,3-bis(3-fluoro-4-(pyrrolidin-1-yl)phenyl)urea $C_{21}H_{24}F_2N_4O$</p>
 <p>4-(dimethylamino)-N-(4-(dimethylamino)phenyl)benzamide $C_{17}H_{21}N_3O$</p>	 <p>6,6'-carbonylbis(azanediyl)bis(1-methylquinolinium) $C_{21}H_{20}N_4O^{2+}$</p>
 <p>4-(4-acetylpiperazin-1-yl)-N-(4-(4-methylpiperazin-1-yl)phenyl)-3-nitrobenzamide $C_{24}H_{30}N_6O_4$</p>	
<p>Furamidine, nafamostat mesylate, and Amb compounds were purchased and tested.</p>	

SUPPORTING INFORMATION

Description of furamide binding poses in minima M1-M4 and U.

The representative structures for each cluster are reported in Figure 6 of the main text. The lowest free energy pose (B) is located in the FES at $d_{CM} \approx 4.8 \text{ \AA}$ and $n_{HB} \approx 14$. The M1 basin is observed at $d_{CM} \approx 10 \text{ \AA}$, $n_{HB} \approx 2$ and is $\approx 2.5 \text{ kcal/mol}$ higher in free energy than B. The cluster analysis of the poses corresponding to this basin shows, in the most populated family, that the A_4 base partially flips outward to stack with one of the compound's phenyl rings. The furan and the other phenyl ring are fully solvent exposed. Two salt bridges between the ligand amidine tails and the phosphate groups of the nucleotides G_5 and G_2 are also observed. The minima M2-M3 are $\approx 4 \text{ kcal/mol}$ higher in free energy than B. In M2 ($d_{CM} \approx 5 \text{ \AA}$, $n_{HB} \approx 8$) the amidine groups establish, on one end, a salt bridge with the A_{17} phosphate group and on the other end an H-bond with N7 atom of the A_4 base. In the basin M3 ($d_{CM} \approx 5 \text{ \AA}$, $n_{HB} \approx 3$) Furamide, almost fully solvated, is bound to the RNA major groove through two H-bonds, established by its amidine tails with the A_4 phosphate group and the O_6 atom of the C_5 base. In the shallow free-energy minimum M4 ($d_{CM} \approx 18 \text{ \AA}$, $n_{HB} \approx 1$), $\approx 6 \text{ kcal/mol}$ higher in free energy than B, Furamide is bound to the 5'-end of the RNA sequence, losing the interactions with both the minor and the major groove floors. One of the two compound guanidine tails forms a salt-bridge with C_{20} phosphate. In the minimum U ($d_{CM} \approx 30 \text{ \AA}$, $n_{HB} \approx 0$), about $\approx 7.5 \text{ kcal/mol}$ higher in free energy than B, direct intermolecular furamide/CAG RNA interactions are absent.